Literature DB >> 12459728

Pancreatic cancer biology and genetics.

Nabeel Bardeesy1, Ronald A DePinho.   

Abstract

Pancreatic ductal adenocarcinoma is an aggressive and devastating disease, which is characterized by invasiveness, rapid progression and profound resistance to treatment. Advances in pathological classification and cancer genetics have improved our descriptive understanding of this disease; however, important aspects of pancreatic cancer biology remain poorly understood. What is the pathogenic role of specific gene mutations? What is the cell of origin? And how does the stroma contribute to tumorigenesis? A better understanding of pancreatic cancer biology should lead the way to more effective treatments.

Entities:  

Mesh:

Year:  2002        PMID: 12459728     DOI: 10.1038/nrc949

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  410 in total

1.  DNA methylation and histone H3-K9 modifications contribute to MUC17 expression.

Authors:  Sho Kitamoto; Norishige Yamada; Seiya Yokoyama; Izumi Houjou; Michiyo Higashi; Masamichi Goto; Surinder K Batra; Suguru Yonezawa
Journal:  Glycobiology       Date:  2010-10-06       Impact factor: 4.313

2.  Mutant KRAS-induced expression of ICAM-1 in pancreatic acinar cells causes attraction of macrophages to expedite the formation of precancerous lesions.

Authors:  Geou-Yarh Liou; Heike Döppler; Brian Necela; Brandy Edenfield; Lizhi Zhang; David W Dawson; Peter Storz
Journal:  Cancer Discov       Date:  2014-10-31       Impact factor: 39.397

3.  Possible predictors of histopathological response to neoadjuvant chemoradiotherapy for rectal cancer.

Authors:  Robert Farkas; Eva Pozsgai; Andrew V Schally; Andras Szigeti; Edit Szigeti; Zoltan Laszlo; Andras Papp; Eva Gomori; Laszlo Mangel; Peter O Horvath; Szabolcs Bellyei
Journal:  J Cancer Res Clin Oncol       Date:  2011-12-08       Impact factor: 4.553

4.  The ARF tumor suppressor inhibits tumor cell colonization independent of p53 in a novel mouse model of pancreatic ductal adenocarcinoma metastasis.

Authors:  Viviane Palhares Muniz; J Matthew Barnes; Seema Paliwal; Xuefeng Zhang; Xiaoyun Tang; Songhai Chen; Kokou D Zamba; Joseph J Cullen; David K Meyerholz; Shari Meyers; J Nathan Davis; Steven R Grossman; Michael D Henry; Dawn E Quelle
Journal:  Mol Cancer Res       Date:  2011-06-02       Impact factor: 5.852

5.  Micronuclei levels in peripheral blood lymphocytes as a potential biomarker for pancreatic cancer risk.

Authors:  Ping Chang; Yanan Li; Donghui Li
Journal:  Carcinogenesis       Date:  2010-11-19       Impact factor: 4.944

6.  Driver mutations: a roadmap for getting close and personal in pancreatic cancer.

Authors:  Murray Korc
Journal:  Cancer Biol Ther       Date:  2010-09-24       Impact factor: 4.742

7.  Structure-activity studies on therapeutic potential of Thymoquinone analogs in pancreatic cancer.

Authors:  Sanjeev Banerjee; Asfar S Azmi; Subhash Padhye; Marjit W Singh; Jubaraj B Baruah; Philip A Philip; Fazlul H Sarkar; Ramzi M Mohammad
Journal:  Pharm Res       Date:  2010-04-27       Impact factor: 4.200

Review 8.  Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine.

Authors:  Erik S Knudsen; Eileen M O'Reilly; Jonathan R Brody; Agnieszka K Witkiewicz
Journal:  Gastroenterology       Date:  2015-09-15       Impact factor: 22.682

9.  Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma.

Authors:  Andrew J Aguirre; Nabeel Bardeesy; Manisha Sinha; Lyle Lopez; David A Tuveson; James Horner; Mark S Redston; Ronald A DePinho
Journal:  Genes Dev       Date:  2003-12-17       Impact factor: 11.361

10.  The c-myc and PyMT oncogenes induce different tumor types in a somatic mouse model for pancreatic cancer.

Authors:  Brian C Lewis; David S Klimstra; Harold E Varmus
Journal:  Genes Dev       Date:  2003-12-17       Impact factor: 11.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.